Navigation Links
Data in NEJM shows Novartis drug Signifor® is first therapy to provide rapid, durable benefit for Cushing's disease patients in Phase III study
Date:3/7/2012

cially available.

Information about Novartis clinical trials for pasireotide can be obtained by healthcare professionals at www.pasporttrials.com.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "can," "potential," "commitment," "look forward to," "expected," "will," or similar expressions, or by express or implied discussions regarding potential marketing approvals for pasireotide or regarding potential future revenues from pasireotide. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with pasireotide to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that pasireotide will be approved for sale in any market, or at any particular time. Nor can there be any guarantee that pasireotide will achieve any particular levels of revenue in the future. In particular, management's expectations regarding pasireotide could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
2. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
3. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
6. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
7. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
8. Feeling Anxious or Distracted? New Research Shows a Cup of Tea Could Help
9. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
10. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
11. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Acsis Inc., ... protection and serialization solutions, has recently posted an ... that addresses current and future needs for companies, ... the old supply chain model no longer work ... technology, including the growth of mobile technology, machine ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2
... WIRE)--Jun 19, 2007 - Javelin,Pharmaceuticals (AMEX: JAV) ... morphine) successfully met its,primary clinical endpoint, the ... over 0-24 hours postoperatively. In this first ... moderate-to-severe pain,after elective orthopedic surgery were given ...
... --,Nuvelo, Inc. today announced the publication of the ... rNAPc2,To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) ... of Cardiology (JACC), demonstrating,that higher-dose (greater than or ... (rNAPc2) reduced the incidence,and duration of ischemia as ...
Cached Medicine Technology:Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 2Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 3Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 4Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 2Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 3Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 4
(Date:7/25/2014)... Phoenix, AZ (PRWEB) July 25, 2014 ... firm offering discount attorney’s fees with regard to ... Hastings provide a wide range of legal services ... of the negligence of another individual or corporation. Free ... of determining the validity of a potential personal ...
(Date:7/25/2014)... for lymphoma may lower men,s fertility, new research indicates. ... cancers of the body,s white blood cells, often affect ... For men, treatment for these cancers can harm or ... within two years of treatment, the researchers cautioned that ... significant side effect before treatment begins. "While many ...
(Date:7/25/2014)... 2014 Parkulture is proud ... and parkour instructor, Jared “JJ” Woods, will be competing ... American Ninja Warrior. The show will premiere on local ... will rerun on the new Esquire Network on Tuesday, ... resident, has been balancing careers as a professional stuntman ...
(Date:7/25/2014)... The Rottenstein Law Group LLP, ... 25 years of experience advocating for plaintiffs with ... announces the launch of its new website, ... believe they have been harmed by the prescription ... information about the severe adverse side effects allegedly ...
(Date:7/25/2014)... Twins, genes may play a greater role in language ... Researchers found more evidence that language traits, ... largely inherited. The study involving 473 sets of ... of language performance for twins than single-born children) was ... finding disputes hypotheses that attribute delays in early language ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Lymphoma Treatment May Harm, Halt Men's Sperm Production 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 2Health News:Jared “JJ” Woods Prepares for American Ninja Warrior City Finals 3Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Genes May Be Key to Language Delay in Kids 2
... is very rare, affecting approximately one in every 100,000 ... i.e. they are born with empty eye sockets. This ... in the normal way in the first 28 days ... fitted with prosthetic eyes to allow normal facial// development. ...
... which occurs when the heart becomes so enlarged that it ... affects 35 in every 100,000 people. Researchers in the United ... journal Science that a defect in the gene phospholamban may ... the flow of calcium through the heart, enabling it to ...
... using a new imaging technique based on Magnetic Resonance ... now, MRI was used to show how Alzheimer's disease ... for memory and learning. And post-mortem studies revealed how ... the first time a three-dimensional time lapse video of ...
... by scientists at the Johns Hopkins School of Public Health ... have called for urgent research into the impact of soya ... chemical in soya can damage the male reproductive organs. Though ... effect on humans, its effects on rats were so severe ...
... published in the February issue of the British Medical Journal ... more at risk of heart disease later in life than ... live infant in Scotland during the years 1981-85, were identified ... miscarriage or repeated miscarriages. Then, during 1981 to 1999, the ...
... blood has been believed to be the most ... heart disease is associated with increased levels of ... LDL(Low-Density Lipoprotein)or 'bad' cholesterol and HDL(High-Density Lipoprotein) or ... researchers in Canada and Sweden are now putting ...
Cached Medicine News:Health News:Miscarriage during pregnancy and heart disease linked 2
... designed for low to medium throughput reading of ... from one to three racks and reads in ... are exported via text files and a list ... integration with other programs. System includes a USB ...
... steel work surface. Pneumatic ... to protect operator, as ... equipment from the workstation. ... for multiple vibration-free work ...
... top with powder-coated steel legs. ... Available in hundreds of sizes ... drawers, light fixtures and ionizing ... in custom building to meet ...
Round, height-adjustable, steel laboratory stools with small footprint for small spaces • Choose options like different height-adjustment mechanism or paint finish. • your choice of color...
Medicine Products: